Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study

被引:11
作者
Woyach, Jennifer A. [1 ]
Barr, Paul M. [2 ]
Kipps, Thomas J. [3 ]
Barrientos, Jacqueline C. [4 ]
Ahn, Inhye E. [5 ]
Ghia, Paolo [6 ,7 ]
Girardi, Vincent [8 ]
Hsu, Emily [8 ]
Jermain, Mandy [8 ]
Burger, Jan A. [9 ]
机构
[1] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA
[2] Univ Rochester, Wilmot Canc Inst, Rochester, NY 14642 USA
[3] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92037 USA
[4] Mt Sinai Comprehens Canc Ctr, Miami Beach, FL 33140 USA
[5] NHLBI, NIH, Lab Lymphoid Malignancies, Bethesda, MD 20814 USA
[6] Univ Vita Salute San Raffaele, I-20132 Milan, Italy
[7] IRCCS Osped San Raffaele, I-20132 Milan, Italy
[8] AbbVie Co, Pharmacyclics LLC, San Francisco, CA 94080 USA
[9] Univ Texas MD Anderson Canc Ctr Houston, Houston, TX 77030 USA
关键词
ibrutinib; chronic lymphocytic leukemia; long-term outcomes; THERAPY; IMPACT; CLL;
D O I
10.3390/cancers15020507
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Ibrutinib is an established standard of care in the first-line treatment of chronic lymphocytic leukemia. Since ibrutinib is given continuously, data on long-term treatment, outcomes, and safety are essential to inform clinical decision making. Here, we describe characteristics and outcomes of patients who received long-term treatment with ibrutinib for >= 5 years in the phase 3 RESONATE-2 study. More than half (58%) of the patients randomly assigned to receive ibrutinib in the RESONATE-2 study continued to benefit from ibrutinib treatment for >= 5 years, regardless of baseline characteristics. Among patients who were on ibrutinib treatment for >= 5 years, complete response rates improved over time through the 5 years. The safety profile of ibrutinib treatment for >= 5 years was consistent with previous reports and no new safety signals were identified. For patients who experienced adverse events, dose modification was effective in resolving adverse events, thereby facilitating continued treatment. Primary results from the phase 3 RESONATE-2 study demonstrated superior efficacy and tolerability with ibrutinib versus chlorambucil in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Here, we describe characteristics and outcomes of patients who received ibrutinib treatment for >= 5 years in RESONATE-2. Patients aged >= 65 years with previously untreated CLL/SLL, without del(17p), were randomly assigned 1:1 to once-daily ibrutinib 420 mg until disease progression/unacceptable toxicity (n = 136) or chlorambucil 0.5-0.8 mg/kg for <= 12 cycles (n = 133). Baseline characteristics in ibrutinib-randomized patients (n = 136) were generally similar between patients on ibrutinib treatment for >= 5 years (n = 79) versus those on treatment for <5 years (n = 57). In patients on ibrutinib treatment for >= 5 years, complete response rates improved over time, reaching 42% by 5 years. Estimated 7-year progression-free survival and overall survival rates were 82% and 94%, respectively. Adverse events (AEs) led to dose reductions in 16/79 patients (20%); these AEs were resolved for 13/16 patients (81%). AEs led to dose holds (>= 7 days) in 45/79 patients (57%); these AEs were resolved for 43/45 patients (96%). More than half (58%) of ibrutinib-randomized patients benefitted from ibrutinib treatment for >= 5 years regardless of baseline characteristics. Dose modification resolved AEs for most patients, thereby facilitating continued treatment.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study
    Huang, Xiaojun
    Qiu, Lugui
    Jin, Jie
    Zhou, Daobin
    Chen, Xiequn
    Hou, Ming
    Hu, Jianda
    Hu, Yu
    Ke, Xiaoyan
    Li, Junmin
    Liang, Yingmin
    Liu, Ting
    Lv, Yue
    Ren, Hanyun
    Sun, Aining
    Wang, Jianmin
    Zhao, Chunting
    Salman, Mariya
    Sun, Steven
    Howes, Angela
    Wang, Jingzhao
    Wu, Peng
    Li, Jianyong
    [J]. CANCER MEDICINE, 2018, 7 (04): : 1043 - 1055
  • [22] Underrepresentation of Small Lymphocytic Lymphoma in Clinical Trials for Chronic Lymphocytic Leukemia
    Puckrin, Robert
    Owen, Carolyn
    Peters, Anthea
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (04) : 636 - 640
  • [23] Infectious lymphadenitis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare, but important, complication
    Bowen, Deborah A.
    Rabe, Kari G.
    Schwager, Susan M.
    Slager, Susan L.
    Call, Timothy G.
    Viswanatha, David S.
    Zent, Clive S.
    [J]. LEUKEMIA & LYMPHOMA, 2015, 56 (02) : 311 - 314
  • [24] Patient Characteristics and Time to Next Treatment With Ibrutinib and Anti-CD20 Monotherapy as First-Line Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Lu, Xiaoxiao
    He, Jinghua
    Ran, Tao
    Wu, Linda
    Panjabi, Sumeet
    Vose, Julie M.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S273 - S273
  • [25] Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary
    Barr, Paul M.
    Owen, Carolyn
    Robak, Tadeusz
    Tedeschi, Alessandra
    Bairey, Osnat
    Burger, Jan A.
    Hillmen, Peter
    Dearden, Claire
    Grosicki, Sebastian
    McCarthy, Helen
    Li, Jian Yong
    Offner, Fritz
    Moreno, Carol
    Jermain, Mandy
    Zhou, Cathy
    Hsu, Emily
    Szoke, Anita
    Kipps, Thomas J.
    Ghia, Paolo
    [J]. FUTURE ONCOLOGY, 2022, 18 (37) : 4047 - 4057
  • [26] Long-Term Outcomes for Patients With Chronic Lymphocytic Leukemia Who Discontinue Ibrutinib
    Jain, Preetesh
    Thompson, Philip A.
    Keating, Michael
    Estrov, Zeev
    Ferrajoli, Alessandra
    Jain, Nitin
    Kantarjian, Hagop
    Burger, Jan A.
    O'Brien, Susan
    Wierda, William G.
    [J]. CANCER, 2017, 123 (12) : 2268 - 2273
  • [27] A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma
    Woyach, J. A.
    Lin, T. S.
    Lucas, M. S.
    Heerema, N.
    Moran, M. E.
    Cheney, C.
    Lucas, D. M.
    Wei, L.
    Caligiuri, M. A.
    Byrd, J. C.
    [J]. LEUKEMIA, 2009, 23 (05) : 912 - 918
  • [28] The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
    Zou, Yi-Xin
    Zhu, Hua-Yuan
    Li, Xiao-Tong
    Xia, Yi
    Miao, Kou-Rong
    Zhao, Si-Shu
    Wu, Yu-Jie
    Wang, Li
    Xu, Wei
    Li, Jian-Yong
    [J]. HEMATOLOGICAL ONCOLOGY, 2019, 37 (04) : 392 - 400
  • [29] Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma
    O'Brien, Susan
    Hillmen, Peter
    Coutre, Steven
    Barr, Paul M.
    Fraser, Graeme
    Tedeschi, Alessandra
    Burger, Jan A.
    Dilhuydy, Marie-Sarah
    Hess, Georg
    Moreno, Carol
    Cramer, Paula
    Liu, Emily
    Chang, Stephen
    Vermeulen, Jessica
    Styles, Lori
    Howes, Angela
    James, Danelle F.
    Patel, Kalpesh
    Graef, Thorsten
    Valentino, Rudolph
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (10) : 648 - +
  • [30] Efficacy and Effectiveness Outcomes of Treatments for Double-Exposed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients: A Systematic Literature Review
    Zuber, Mohammed
    Akkala, Sreelatha
    Li, Niying
    Veettil, Sajesh K.
    Tan, Chia Jie
    Zapata, Lorenzo Villa
    [J]. CANCER MEDICINE, 2024, 13 (18):